Skip to main content
Top
Published in: Clinical Rheumatology 5/2016

01-05-2016 | Original Article

The effect of resveratrol on the recurrent attacks of gouty arthritis

Authors: Haiyan Chen, Shucong Zheng, Yuankai Wang, Huiqing Zhu, Qiong Liu, Yu Xue, Jianhua Qiu, Hejian Zou, Xiaoxia Zhu

Published in: Clinical Rheumatology | Issue 5/2016

Login to get access

Abstract

Gouty arthritis is characterized by inflammation induced by monosodium urate (MSU) crystal deposition, which is resulted by an increase of serum urate concentration. The management of gout, especially the recurrent acute attacks of chronic gouty arthritis, is still a problem to be resolved. In this study, we aimed to develop the preventive and therapeutic effect of resveratrol on gouty arthritis. MSU was used to induce gouty arthritis in the foot pad of C57BL/6 mice. Yeast polysaccharide and potassium oxonate were used to induce hyperuricemia in Kunming mice. Resveratrol was intraperitoneal injected to the mice in the treatment group. The pad inflammation and the level of serum uric acid were investigated to estimate the effect of resveratrol in gouty arthritis. Hyperuricemia was significantly detected in the mice treated with yeast polysaccharide and potassium oxonate, and gouty arthritis was successfully induced with MSU in mice. We further identified that resveratrol inhibited pad swelling and pad 99mTc uptake in gouty mice. Moreover, serum uric acid level was also decreased by resveratrol in hyperuricemia mice. This study highlighted that resveratrol might be applied to prevent the recurrent acute attack of gouty arthritis because of its inhibition of articular inflammation and down-regulation of serum uric acid.
Literature
1.
go back to reference Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al (2012) American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431–1446CrossRef Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al (2012) American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431–1446CrossRef
2.
go back to reference Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447–1461CrossRef Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447–1461CrossRef
4.
go back to reference Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L et al (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71:1765–1770CrossRefPubMed Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L et al (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71:1765–1770CrossRefPubMed
5.
go back to reference Rodevand E, Sletvold O, Kvande KT (2004) Side effects off allopurinol. Tidsskr Nor Laegeforen 124:2618–2619PubMed Rodevand E, Sletvold O, Kvande KT (2004) Side effects off allopurinol. Tidsskr Nor Laegeforen 124:2618–2619PubMed
6.
go back to reference Hilmi BA, Asmahan MI, Rosman A (2012) Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. Med J Malays 67:125–126 Hilmi BA, Asmahan MI, Rosman A (2012) Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. Med J Malays 67:125–126
7.
go back to reference Borra MT, Smith BC, Denu JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280:17187–17195CrossRefPubMed Borra MT, Smith BC, Denu JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280:17187–17195CrossRefPubMed
8.
go back to reference Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191–196CrossRefPubMed Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191–196CrossRefPubMed
9.
go back to reference Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122CrossRefPubMed Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122CrossRefPubMed
10.
go back to reference Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, Chatterjee M et al (2010) Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res 27:1080–1091CrossRefPubMed Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, Chatterjee M et al (2010) Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res 27:1080–1091CrossRefPubMed
11.
go back to reference Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X et al (2011) Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS One 6:e27081CrossRefPubMedPubMedCentral Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X et al (2011) Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS One 6:e27081CrossRefPubMedPubMedCentral
12.
go back to reference Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B (2007) Effects of resveratrol in inflammatory arthritis. Inflammation 30:1–6CrossRefPubMed Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B (2007) Effects of resveratrol in inflammatory arthritis. Inflammation 30:1–6CrossRefPubMed
13.
go back to reference Wang KT, Chen LG, Tseng SH, Huang JS, Hsieh MS, Wang CC (2011) Anti-inflammatory effects of resveratrol and oligostilbenes from Vitis thunbergii var. taiwaniana against lipopolysaccharide-induced arthritis. J Agric Food Chem 59:3649–3656CrossRefPubMed Wang KT, Chen LG, Tseng SH, Huang JS, Hsieh MS, Wang CC (2011) Anti-inflammatory effects of resveratrol and oligostilbenes from Vitis thunbergii var. taiwaniana against lipopolysaccharide-induced arthritis. J Agric Food Chem 59:3649–3656CrossRefPubMed
14.
go back to reference Post AM, Katsikis PD, Tait JF, Geaghan SM, Strauss HW, Blankenberg FG (2002) Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J Nucl Med 43:1359–1365PubMed Post AM, Katsikis PD, Tait JF, Geaghan SM, Strauss HW, Blankenberg FG (2002) Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J Nucl Med 43:1359–1365PubMed
15.
go back to reference Carroll JJ, Coburn H, Douglass R, Babson AL (1971) A simplified alkaline phosphotungstate assay for uric acid in serum. Clin Chem 17:158–160PubMed Carroll JJ, Coburn H, Douglass R, Babson AL (1971) A simplified alkaline phosphotungstate assay for uric acid in serum. Clin Chem 17:158–160PubMed
16.
go back to reference Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H et al (2009) Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 60:3651–3662CrossRefPubMedPubMedCentral Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H et al (2009) Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 60:3651–3662CrossRefPubMedPubMedCentral
17.
go back to reference Joosten LA, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M, Helsen MM, van den Bersselaar LA, Oppers-Walgreen B et al (2008) T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum 58:98–108CrossRefPubMed Joosten LA, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M, Helsen MM, van den Bersselaar LA, Oppers-Walgreen B et al (2008) T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum 58:98–108CrossRefPubMed
18.
go back to reference Palsamy P, Subramanian S (2008) Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 62:598–605CrossRefPubMed Palsamy P, Subramanian S (2008) Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 62:598–605CrossRefPubMed
19.
go back to reference Bruckbauer A, Zemel MB, Thorpe T, Akula MR, Stuckey AC, Osborne D et al (2012) Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond) 9:77CrossRef Bruckbauer A, Zemel MB, Thorpe T, Akula MR, Stuckey AC, Osborne D et al (2012) Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond) 9:77CrossRef
20.
go back to reference Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, Nozawa Y et al (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373:423–428CrossRefPubMed Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, Nozawa Y et al (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373:423–428CrossRefPubMed
21.
22.
go back to reference Salminen A, Ojala J, Huuskonen J, Kauppinen A, Suuronen T, Kaarniranta K (2008) Interaction of aging-associated signaling cascades: inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci 65:1049–1058CrossRefPubMed Salminen A, Ojala J, Huuskonen J, Kauppinen A, Suuronen T, Kaarniranta K (2008) Interaction of aging-associated signaling cascades: inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci 65:1049–1058CrossRefPubMed
23.
go back to reference Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, Stoelben E et al (2010) Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol Exp Ther 335:788–798CrossRefPubMed Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, Stoelben E et al (2010) Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol Exp Ther 335:788–798CrossRefPubMed
24.
go back to reference Chung EY, Kim BH, Hong JT, Lee CK, Ahn B, Nam SY et al (2010) Resveratrol down-regulates interferon-gamma-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem 22:902–909CrossRefPubMed Chung EY, Kim BH, Hong JT, Lee CK, Ahn B, Nam SY et al (2010) Resveratrol down-regulates interferon-gamma-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem 22:902–909CrossRefPubMed
25.
go back to reference Wu XW, Muzny DM, Lee CC, Caskey CT (1992) Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34:78–84CrossRefPubMed Wu XW, Muzny DM, Lee CC, Caskey CT (1992) Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34:78–84CrossRefPubMed
26.
go back to reference Bomalaski JS, Clark MA (2004) Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 6:240–247CrossRefPubMed Bomalaski JS, Clark MA (2004) Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 6:240–247CrossRefPubMed
27.
go back to reference Hirai A, Kumagai A (1982) Animal model for gout. Jikken Dobutsu 31:143–151PubMed Hirai A, Kumagai A (1982) Animal model for gout. Jikken Dobutsu 31:143–151PubMed
28.
go back to reference Chen L, Yin H, Lan Z, Ma S, Zhang C, Yang Z et al (2011) Anti-hyperuricemic and nephroprotective effects of Smilax china L. J Ethnopharmacol 135:399–405CrossRefPubMed Chen L, Yin H, Lan Z, Ma S, Zhang C, Yang Z et al (2011) Anti-hyperuricemic and nephroprotective effects of Smilax china L. J Ethnopharmacol 135:399–405CrossRefPubMed
29.
go back to reference Xu WA, Yin L, Pan HY, Shi L, Xu L, Zhang X et al (2013) Study on the correlation between constituents detected in serum from Rhizoma Smilacis Glabrae and the reduction of uric acid levels in hyperuricemia. J Ethnopharmacol 150:747–754CrossRefPubMed Xu WA, Yin L, Pan HY, Shi L, Xu L, Zhang X et al (2013) Study on the correlation between constituents detected in serum from Rhizoma Smilacis Glabrae and the reduction of uric acid levels in hyperuricemia. J Ethnopharmacol 150:747–754CrossRefPubMed
Metadata
Title
The effect of resveratrol on the recurrent attacks of gouty arthritis
Authors
Haiyan Chen
Shucong Zheng
Yuankai Wang
Huiqing Zhu
Qiong Liu
Yu Xue
Jianhua Qiu
Hejian Zou
Xiaoxia Zhu
Publication date
01-05-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2836-3

Other articles of this Issue 5/2016

Clinical Rheumatology 5/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.